Serum biomarkers in head and neck squamous cell cancer

JAMA Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 1, 2014, Pages 5-11

  Kaskas, Nadine M ^a   Moore Medlin, Tara ^a   McClure, Gloria B ^a   Ekshyyan, Oleksandr ^a,b   Vanchiere, John A ^a   Nathan, Cherie Ann O ^a,b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GROWTH RELATED ONCOGENE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; ONCOGENE; PILOT STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84892682755     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.5688     Document Type: Article

References (35)

1. thed. [book published online March 8, 2013 by Journal of Oncology]. http://www. cancernetwork.com/cancer-management/head-and-neck-tumors/page/0/1. Accessed September 5, 2013.
2. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012;122(6):1951-1957.
3. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med. 2010;77(6):684-699.
4. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer. 2005;103(9):1843-1849.
5. Hoffmann TK, Bier H, Whiteside TL. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2004; 53(12):1055- 1067.
6. Warnakulasuriya S. Areca nut use following migration and its consequences. Addict Biol. 2002;7(1):127-132.
7. Trivedy CR, Craig G, Warnakulasuriya S. The oral health consequences of chewing areca nut. Addict Biol. 2002;7(1):115-125.
8. Lathers DM, Young MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine. 2004;25(5):220-228.
9. Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):965-974.
10. Human Cytokine/Chemokine Magnetic Bead Panel Assay. Millipore Research. EMD Millipore. 2012. http://www.millipore.com/catalogue/item/hcytomag-60k. Accessed June 15, 2012.
11. Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9:113.
12. Clendenen TV, Koenig KL, Arslan AA, et al. Factors associated with inflammation markers, a cross-sectional analysis. Cytokine. 2011;56(3):769-778.
13. Satoh T, Tollerud DJ, Guevarra L, Rakue Y, Nakadate T, Kagawa J. Chemiluminescence assays for cytokines in serum: influence of age, smoking, and race in healthy subjects [in Japanese]. Arerugi. 1995;44(7):661-669.
14. Sekikawa A, Kadowaki T, Curb JD, et al; ERA JUMP Study Group. Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men. J Interferon Cytokine Res. 2010;30(7):541-548.
15. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
16. Liu RY, Zhu YH, Zhou L, et al. Adenovirusmediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma. J Transl Med. 2012;10:256.
17. Tate DJ Jr, Patterson JR, Velasco-Gonzalez C, et al. Interferon-γ- induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci. 2012;8(8):1109-1120.
18. Hastie C, Masters JR, Moss SE, Naaby-Hansen S. Interferon-γ reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem. 2008;283(18):12595-12603.
19. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129(2):550-564.
20. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175-190.
21. Obiri NI, Husain SR, DebinskiW, Puri RK. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res. 1996;2(10):1743-1749.
22. Serve H, Oelmann E, Herweg A, et al. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res. 1996;56(15):3583-3588.
23. Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4(10):1072-1086.
24. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317-343.
25. Bhattacharjee A, ShuklaM, Yakubenko VP, Mulya A, Kundu S, Cathcart MK. IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic Biol Med. 2013;54:1-16.
26. BogelsM, Braster R, Nijland PG, et al. Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology. 2012;1(6):798-809.
27. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol. 2011;131(6):1322-1330.
28. Luo X, Yu Y, Liang A, et al. Intratumoral expression of MIP-1β induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol. 2004;1(3):199-204.
29. Luo XL, Xie YA, Kuang ZP, Wu JN, Liang AM. Effects of hMIP-1β gene modification on in vivo tumorigenicity and vaccine efficacy of tumor cells [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2008;30(2):97-102.
30. Trellakis S, Bruderek K, Dumitru CA, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells, and expansion in advanced disease. Int J Cancer. 2011;129(9):2183- 2193.
31. Michiels K, Schutyser E, Conings R, et al. Carcinoma cell-derived chemokines and their presence in oral fluid. Eur J Oral Sci. 2009;117(4):362-368.
32. Chakraborty K, Bose A, Pal S, et al. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int Immunopharmacol. 2008;8(2):330-340.
33. Li J, Zhang XS, Xie D, et al. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression. Cancer Biol Ther. 2007;6(12):1997-2004.
34. Chang KP, Chang YT, Wu CC, et al. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck. 2011;33(6):886-897.
35. Melillo RM, Guarino V, Avilla E, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203-6215.